Mankind Pharmaceutical down 2.76 percent to Rs 2,560.05 following a 16.2% drop in the company’s consolidated net profit to Rs 380.23 crore in Q3 FY25 compared to Rs 453.76 crore in Q3 FY24.
In the third quarter of FY25, however, income from operations climbed 23.9% year over year (YoY) to Rs 3,230 crore.
In Q3 of FY25, profit before tax was Rs 497.33 crore, representing an 11.56% decrease from the Rs 562.32 crore achieved in Q3 of FY24.
In the December 2024 quarter, EBITDA increased 36.4% year over year to Rs 833 crore. In Q3 of FY25, the EBITDA margin increased to 25.8% from 23.4% in the same quarter the year before.
In the third quarter of FY25, foreign revenue increased by 120.8% YoY to Rs 457 crore, while domestic revenue increased by 15.5% YoY to Rs 2,773 crore.
A rise in base business, bolstered by new launches over the past 12 months and BSV consolidation, drove export growth. The company launched one new product in the US during the quarter, bringing the total number of items launched to 42.
With consistent growth across all major brands, the company’s consumer healthcare division reported a 30% increase in revenue to Rs 193 crore in Q3 FY25. Manforce Condom, Gas-o-fast, and HealthOk saw strong growth in secondary sales of 13%, 28%, and 26% YoY, respectively, and gained significant traction with recent strategic launches, such as Manforce Epic (Premium category), Nimulid (Pain Management), etc.
In FY25’s third quarter, cash flow from operations was Rs 460 crore.
“In Q3 FY25, we delivered a healthy revenue growth of 24% YoY with a great adjusted EBITDA margin of 27.7%, led by ongoing outperformance in chronic, significant recovery in OTC, and consolidation of BSV,” stated Rajeev Juneja, vice chairman and managing director of Mankind Pharma. OTC’s 30% YoY sales increase was bolstered by previous year’s strategic efforts.
With an emphasis on protecting branding, increasing productivity, and implementing best practices to guarantee long-term sustainable growth, the integration of BSV is proceeding as planned. 2024 has been a year of transformation; BSV now has a high-entry barrier super specialty portfolio, a fast-growing specialty chronic section, a consistent base business, and a high potential over-the-counter company.
-NSH Digidesk
